目录号 | 产品详情 | 靶点 | |
---|---|---|---|
T61973 | Others | ||
Anticancer agent 79 (compound 3d) 是一种抗癌化合物,具有良好的抗乳腺癌 (anti-breast cancer) 活性。Anticancer agent 79 对 T47-D 细胞表现出良好的细胞毒性活性(IC50= 13.64±0.26 μM)。 | |||
T61378 | Others | ||
Anticancer agent 29 (Compd E/Z-6f) exhibits potent anticancer activity, as indicated by IC50 values of 0.054 μM, 0.127 μM, 0.129 μM, and 0.396 μM for CDK2, CDK1, CDK4, and CDK6, respectively [1]. | |||
T61097 | Others | ||
Anticancer agent 70 (Compound 21) is a potent anticancer compound that demonstrates remarkable cytotoxicity against multiple human cancer cell lines. It induces G0/G1-cell cycle arrest and concurrently elevates the levels of p53 and p21 proteins. Furthermore, Anticancer agent 70 induces ATP depletion and disruption of the mitochondrial membrane potential [1]. | |||
T72479 | Others | ||
Anticancer agent 66 是一种抗癌剂。Anticancer agent 66 在 MCF-7 细胞中诱导细胞凋亡 (apoptosis) 并增加亚 G1 细胞群。Anticancer agent 66 是一种环丙沙星类似物。 | |||
T62754 | Others | ||
Anticancer agent 34 (compound 9) 是一种磺酰脲类衍生物,也是一种有效的抗微生物剂和抗癌剂。Anticancer agent 34 对蕈状芽孢杆菌、大肠杆菌和白色念珠菌的微生物生长表现出抑制作用 (MIC: 0.039-0.156 mg/ml)。Anticancer agent 34 能够抑制 A549 细胞 (IC50: 8.4 μg/ml)、PC3 细胞 (IC50: 7.8 μg/ml) 的生长。 | |||
T62523 | Others | ||
Anticancer agent 40 (compound 3e) 是一种有效的抗癌剂。Anticancer agent 40 具有抗癌作用,能够作用于 SKBR-3 细胞 (IC50: 0.94 nM)、SKOV-3 细胞 (IC50: 0.98 nM)、PC-3 细胞 (IC50: 0.96 nM)、U-87 细胞 (IC50: 0.95 nM)、HDF 细胞 (IC50: 2.13 nM)。 | |||
T85670 | |||
Anticancer agent 129 (Compound 3a) is a quinoline derivative predicted to have anti-cancer activity [1]. | |||
T61582 | Others | ||
Anticancer agent 57 (compound 14) demonstrates potent inhibition of MDA-MB-231, MDA-MB-468, and MCF-7 cell lines, with IC 50 values ranging from 6.43 to 8.00 μM. Additionally, this agent induces cell cycle arrest and promotes apoptosis. In vivo studies using nude mice xenografted with MADMB-231 cells have shown that Anticancer agent 57 effectively inhibits tumor growth. Consequently, Anticancer agent 57 can serve as a valuable tool for researching triple negative breast cancer (TNBC) [1]. | |||
T83094 | Others | ||
Anticanceragent 103 (Compound 2k)为高效抗癌化合物。 | |||
T83092 | Others | ||
Anticanceragent 112,是一种用于癌症研究的强效抗癌试剂。 |
目录号 | 产品名/同用名 | 种属 | 表达系统 | ||
---|---|---|---|---|---|
TMPY-05033 | 5T4/TPBG Protein, Human, Recombinant (aa 60-345, His) | Human | HEK293 Cells | ||
Trophoblast glycoprotein (TPBG), also known as 5T4, is the therapeutic target of several anticancer agents currently in clinical development, largely due to its high expression in tumors and low expression in normal adult tissues. 5T4/TPBG Protein, Human, Recombinant (aa 60-345, His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 33.1 kDa and the accession number is Q13641.
|
|||||
TMPY-04644 | PDGFB Protein, Human, Recombinant (His) | Human | P. pastoris (Yeast) | ||
Platelet-derived growth factor-B (PDGFB) is necessary for normal cardiovascular development. The administration of PDGFB alone normalized tumor vasculature by increasing periendothelial coverage and vascular functionality. Interestingly, this effect exerted by PDGFB was also observed in the presence of DAPT. So PDGFB is able to improve tumor vascularity and allows the anticancer action of DAPT in the tumor. PDGFB Protein, Human, Recombinant (His) is expressed in yeast with His tag. The predicted molecular weight is 14.3 kDa and the accession number is P01127-2.
|
|||||
TMPY-06191 | 5T4/TPBG Protein, Mouse, Recombinant (His) | Mouse | HEK293 Cells | ||
Trophoblast glycoprotein (TPBG), also known as 5T4, is the therapeutic target of several anticancer agents currently in clinical development, largely due to its high expression in tumors and low expression in normal adult tissues. 5T4/TPBG Protein, Mouse, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 37.2 kDa and the accession number is Q9Z0L0.
|
|||||
TMPY-06214 | 5T4/TPBG Protein, Mouse, Recombinant (hFc) | Mouse | HEK293 Cells | ||
Trophoblast glycoprotein (TPBG), also known as 5T4, is the therapeutic target of several anticancer agents currently in clinical development, largely due to its high expression in tumors and low expression in normal adult tissues. 5T4/TPBG Protein, Mouse, Recombinant (hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 62.5 kDa and the accession number is Q9Z0L0.
|
|||||
TMPK-01310 | Syndecan-1 Protein, Rabbit, Recombinant (His) | Rabbit | HEK293 Cells | ||
CD138 (syndecan-1, Sdc-1) is a member of the syndecan family that comprises heparan sulfate proteoglycans. CD138 is significant for cell-cell and cell-matrix interactions.CD138 plays a crucial role in carcinogenesis and is an attractive target for anticancer treatment with heparanase inhibitors and anti-CD138 antibodies for immunotherapy.
|
|||||
TMPY-06317 | 5T4/TPBG Protein, Human, Recombinant (aa 1-355, His) | Human | HEK293 Cells | ||
Trophoblast glycoprotein (TPBG), also known as 5T4, is the therapeutic target of several anticancer agents currently in clinical development, largely due to its high expression in tumors and low expression in normal adult tissues. 5T4/TPBG Protein, Human, Recombinant (aa 1-355, His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 36.15 kDa and the accession number is NP_006661.1.
|
|||||
TMPK-00721 | CX3CL1/Fractalkine Protein, Mouse, Recombinant (His & Avi), Biotinylated | Mouse | HEK293 Cells | ||
Fractalkine/CX3C chemokine ligand 1 (CX3CL1) is a chemokine involved in the anticancer function of lymphocytes-mainly NK cells, T cells and dendritic cells. Its increased levels in tumors improve the prognosis for cancer patients, although it is also associated with a poorer prognosis in some types of cancers, such as pancreatic ductal adenocarcinoma.
|
|||||
TMPY-05077 | PDGFB Protein, Rhesus, Recombinant (His) | Rhesus | P. pastoris (Yeast) | ||
Platelet-derived growth factor-B (PDGFB) is necessary for normal cardiovascular development. The administration of PDGFB alone normalized tumor vasculature by increasing periendothelial coverage and vascular functionality. Interestingly, this effect exerted by PDGFB was also observed in the presence of DAPT. So PDGFB is able to improve tumor vascularity and allows the anticancer action of DAPT in the tumor. PDGFB Protein, Rhesus, Recombinant (His) is expressed in yeast with His tag. The predicted molecular weight is 14.2 kDa and the accession number is A0A1D5Q4I7.
|
|||||
TMPK-00060 | IL-17B Protein, Mouse, Recombinant (His) | Mouse | E. coli | ||
IL-17A, the prototypic member of the IL-17 family, several experimental findings strongly support the role of the IL-17B/IL-17 receptor B (IL-17RB) pathway in tumorigenesis and resistance to anticancer therapies. IL-17B/IL-17RB expression patterns and biological activities in cancer and highlight issues that remain to be addressed to better characterize IL-17B and its receptor as potential targets for enhancing the effectiveness of the existing cancer therapies.
|
|||||
TMPY-04877 | PDGFB Protein, Mouse, Recombinant (His) | Mouse | P. pastoris (Yeast) | ||
Platelet-derived growth factor-B (PDGFB) is necessary for normal cardiovascular development. The administration of PDGFB alone normalized tumor vasculature by increasing periendothelial coverage and vascular functionality. Interestingly, this effect exerted by PDGFB was also observed in the presence of DAPT. So PDGFB is able to improve tumor vascularity and allows the anticancer action of DAPT in the tumor. PDGFB Protein, Mouse, Recombinant (His) is expressed in yeast with His tag. The predicted molecular weight is 14.2 kDa and the accession number is Q8R3X9.
|
|||||
TMPY-02395 | PDGFB Protein, Cynomolgus, Recombinant (mFc) | Cynomolgus | HEK293 Cells | ||
Platelet-derived growth factor-B (PDGFB) is necessary for normal cardiovascular development. The administration of PDGFB alone normalized tumor vasculature by increasing periendothelial coverage and vascular functionality. Interestingly, this effect exerted by PDGFB was also observed in the presence of DAPT. So PDGFB is able to improve tumor vascularity and allows the anticancer action of DAPT in the tumor. PDGFB Protein, Cynomolgus, Recombinant (mFc) is expressed in HEK293 mammalian cells with mFc tag. The predicted molecular weight is 38.9 kDa and the accession number is G7PFK7.
|
|||||
TMPK-00710 | Claudin-4 Protein-VLP, Human, Recombinant | Human | HEK293 Cells | ||
Claudin-4 (CLDN4) is a key component of tight junctions (TJs) in epithelial cells. CLDN4 is overexpressed in many epithelial malignancies and correlates with cancer progression. Changes in CLDN4 expression have been associated with epigenetic factors (such as hypomethylation of promoter DNA), inflammation associated with infection and cytokines, and growth factor signaling. CLDN4 helps to maintain the tumor microenvironment by forming TJs and acts as a barrier to the entry of anticancer drugs into tumors.
|
|||||
TMPY-05076 | PDGFB Protein, Canine, Recombinant (His) | Canine | P. pastoris (Yeast) | ||
Platelet-derived growth factor-B (PDGFB) is necessary for normal cardiovascular development. The administration of PDGFB alone normalized tumor vasculature by increasing periendothelial coverage and vascular functionality. Interestingly, this effect exerted by PDGFB was also observed in the presence of DAPT. So PDGFB is able to improve tumor vascularity and allows the anticancer action of DAPT in the tumor. PDGFB Protein, Canine, Recombinant (His) is expressed in yeast with His tag. The predicted molecular weight is 14.9 kDa and the accession number is Q6Q7I7.
|
|||||
TMPJ-00247 | METAP1 Protein, Human, Recombinant | Human | E. coli | ||
Methionine Aminopeptidase 1 is a member of the M24 family of metalloproteases. METAP1 plays an important role in G(2)/M phase regulation of the cell cycle and may serve as a promising target for the discovery and development of new anticancer agents. METAP1 and METAP2 have different substrate specificity due to the differences in both size and shape of the active sites. The proteolytic removal of N-terminal methionine from nascent peptides is catalyzed by a family of enzymes known as methionine aminopeptidases (MetAPs) and is essential for cell growth. Inhibition of METAPs provides a novel strategy in developing anti-cancer drugs.
|
|||||
TMPY-01865 | BLMH Protein, Mouse, Recombinant (His) | Mouse | E. coli | ||
The papain superfamily member bleomycin hydrolase (BLMH) is a cytoplasmic cysteine peptidase that is highly conserved through evolution. The only known activity of the enzyme is metabolic inactivation of the glycopeptide bleomycin (BLM), an essential component of combination chemotherapy regimens for cancer. The papain superfamily member bleomycin hydrolase (BLMH) is a neutral cysteine protease with structural similarity to a 20S proteasome. Bleomycin (BLM), a clinically used glycopeptide anticancer agent. BLMH is an essential protectant against BLM-induced death and has an important role in neonatal survival and in maintaining epidermal integrity. Sequencing revealed several putative sites phosphorylated by different types of protein kinases, but no signal sequence, transmembrane domain, N-linked glycosylation site or DNA-binding motif.
|
|||||
TMPY-02072 | HSF1 Protein, Human, Recombinant (His) | Human | E. coli | ||
Heat shock factor protein 1, also known as heat shock transcription factor 1, HSF1, and HSTF1, is a cytoplasm and nucleus protein that belongs to the HSF family. HSF1 is the major transcription factor of HSPs (heat shock proteins) in response to various stresses. Wild type HSF1 (heat shock transcriptional factor 1) is normally inactive. HSF1 / HSTF1 is a DNA-binding protein that specifically binds heat shock promoter elements (HSE) and activates transcription. In higher eukaryotes, HSF is unable to bind to the HSE unless the cells are heat shocked. HSF1 / HSTF1 protects cells and organisms against various types of stress, either by triggering a complex response that promotes cell survival or by triggering cell death when stress-induced alterations cannot be rescued. HSF1 / HSTF1 is the key protein in regulating the stress response. It can be activated under heat, oxidative, or other stress conditions. Dominant-positive and dominant-negative HSF1 are two types of HSF1 mutants. Both of them gain DNA binding activity in the absence of stress. Also, dominant-positive HSF1 acquires transcriptional activity, which dominant-negative HSF1 does not acquire. HSF1 / HSTF1 was also reported to contribute to cell resistance against genotoxic stress, such as that caused by doxorubicin, an anticancer drug in common clinical use.
|